Based on these observations, the relationship between tumors and PD-1/PD-L1/PD-L2 has been studied widely, and PD-1/PD-L1-targeted inhibitors, as cancer immunotherapy, have been developed (11, 13, 17, 29, 44–46). Here, PDCD1 is linked to cancer.